U lcerative colitis (UC) is a chronic inflammatory disorder of the large intestine characterized by bloody diarrhea, abdominal pain and cramping, and urgency and tenesmus, which can negatively affect daily functioning and quality of life. 1 The goals of therapy include the induction of remission and mucosal healing. For patients with mild to moderate disease, this may be achieved with mesalamines with or without corticosteroids (CSs). Mesalamine and steroids also may be useful in patients with more distal disease and may aid in symptom resolution in patients with more extensive disease. 2 For more severe disease and in hospitalized patients, CSs may be administered intravenously. Limitations of CS therapy include a high incidence of short-and long-term adverse effects and the inability to maintain remission. 3 Patients who experience frequent disease relapse or are resistant to or dependent on CSs often are treated with purine antimetabolites, including azathioprine (AZA) or 6-mercaptopurine (6-MP), to maintain remission. 2 Such patients also may be candidates for treatment with monoclonal antibodies targeting tumor necrosis factor-a (TNF-a), which have shown efficacy in inducing and maintaining remission in patients with UC. 4 However, treatment guidelines routinely recommend the use of TNF-a antagonists only after failure of conventional nonbiologic therapy, including the purine antimetabolites AZA and 6-MP. [5] [6] [7] The comparative efficacies of TNF-a antagonists vs purine antimetabolites or vs the combination of TNF-a antagonists and purine antimetabolites are important questions relevant to management of UC. This trial was designed to compare the efficacy of the TNF-a antagonist infliximab (IFX), AZA, or the combination of the 2 drugs (IFX/ AZA) in the treatment of patients with moderate to severe UC.
Methods

Ethical Issues
The study was conducted in accordance with Good Clinical Practices guidelines. 8 The institutional review board of each center approved the protocol, and all study participants provided informed written consent. All authors had access to the Abbreviations used in this paper: AEs, adverse events; ATI, antibodies to infliximab; AZA, azathioprine; CI, confidence interval; CS, corticosteroid; IBDQ, Inflammatory Bowel Disease Questionnaire; IFX, infliximab; PBO, placebo; SF-36, 36-item Short Form Health Survey; 6-MP, 6-mercaptopurine; TNF-a, tumor necrosis factor a; UC, ulcerative colitis. study data and were required to review and approve the final manuscript.
Study Design and Procedures
UC SUCCESS (NCT00537316, protocol number P04807) was a randomized, double-blind, double-dummy trial evaluating the safety and efficacy of 16 weeks of IFX monotherapy, AZA monotherapy, and IFX/AZA combination therapy in the treatment of patients with moderate to severe, active UC. The study was performed at 62 centers from November 2007 through February 2010.
Randomization was performed centrally using an adaptive randomization procedure stratified by whether patients previously used immunomodulators such as AZA and cyclosporine. Patients were randomized in a 1:1:1 ratio to receive IFX, AZA, or combination IFX/AZA treatment. Patients in the IFX group received 5 mg/kg intravenous IFX at weeks 0, 2, 6, and 14 plus daily oral placebo (PBO) capsules. Patients in the IFX group who were nonresponders at week 8 (partial Mayo score improvement from baseline of <1) also received PBO infusions at weeks 8 and 10. Patients in the AZA group received 2.5 mg/kg AZA oral capsules daily plus intravenous PBO infusions at weeks 0, 2, and 6. For patients who responded to AZA at week 8, a PBO infusion also was received at week 14. For patients who were nonresponders to AZA at week 8 (partial Mayo score improvement from baseline of <1), IFX rescue infusions were administered at weeks 8, 10, and 14 while continuing AZA therapy. Patients in the combination IFX/AZA group received IFX 5 mg/kg at weeks 0, 2, 6, and 14 and also received 2.5 mg/kg AZA capsules daily. Patients in this group who were nonresponders at week 8 also received PBO infusions at weeks 8 and 10. Thiopurine methyltransferase was not assayed at study enrollment. Patients with a known sensitivity to administered study medications were excluded from the study. A strategy for dose reduction and discontinuation of AZA was followed during the study if a patient developed leukopenia, transaminitis, or pancreatitis. Details of the study design are shown in Supplementary Figure 1A .
All concomitant therapies at baseline were held stable throughout the study. Patients taking CSs at baseline were tapered to 0 mg by week 14 unless medically contraindicated. It was recommended that for patients who were receiving a dosage of more than 20 mg/day of prednisone or equivalent at enrollment, the CS dose be tapered daily by 5 mg/week to 20 mg/day, then by 2.5 mg/week. For patients who were receiving 20 mg/day or less of prednisone or equivalent at enrollment, the daily dose was to be tapered by 2.5 mg/week.
After the initial randomized treatment phase of the study, a continuation study was planned to evaluate which of 2 openlabel maintenance treatment regimens was superior for maintaining steroid-free remission. Patients who had achieved CS-free remission at week 16 or patients who were not enrolled in the study but had been treated with IFX for a maximum of 6 months with or without AZA/6-MP and were in CS-free remission could enter the follow-up study, which included a randomized portion and an observational portion (Supplementary Figure 1B) . An enrollment target of 600 patients was planned for the initial randomized treatment phase to fully enroll 200 patients in the longer-term follow-up study. However, in October 2009, the sponsor decided to terminate enrollment in this study because of a higher-than-expected incidence of serious infusion reactions in patients who received an intermittent IFX regimen with re-induction in a separate, long-term study of patients with psoriasis (RESTORE2, NCT00358670). 9 As a result, only 239 patients were randomized to the initial treatment phase. Only 13 of the planned 200 patients were randomized for the follow-up study; therefore, the data are not reported here.
Patients
Eligible patients were at least 18 years of age (the minimum age was increased to 21 years of age after the study started) with moderate to severe UC as defined by Mayo score at baseline 10 ; moderate and severe disease were defined as Mayo scores of 6-8 and 9-12, respectively. Patients had endoscopic evidence of UC, as determined by sigmoidoscopy, within 14 days before baseline. Patients were required to have responded inadequately to a course of CSs with or without mesalamine within the past 12 weeks. Patients who were taking CSs could enter the study if they were on a stable dose (30 mg prednisone or equivalent) for at least 2 weeks before enrollment. All patients were required to be TNF-a antagonist-naive. Patients also were required to be either AZA-naive or free from AZA treatment for at least 3 months before enrollment. Prohibited medications at study entry included methotrexate, calcineurin inhibitors (tacrolimus, cyclosporine), antibiotics, rectal therapy with CSs or mesalamine, and antimotility agents or laxatives.
Patients were excluded if they had been hospitalized for extensive severe UC or had experienced recent gastrointestinal surgery, bowel obstruction, stricture of the colon, previous colonic resection, documented colonic dysplasia, previous tuberculosis or other granulomatous infection, a recent episode of an opportunistic infection (within 2 months of screening), active infection with hepatitis B or C, infection with the human immunodeficiency virus, history of a demyelinating disease, systemic lupus erythematosus, malignancy, congestive heart failure, or a transplanted organ.
Evaluation of Efficacy and Safety
The Mayo score, 10 Inflammatory Bowel Disease Questionnaire (IBDQ), 11 the Short-Form Health Survey (SF-36), 12 and fecal calprotectin levels were assessed at baseline and weeks 8 and 16. Sigmoidoscopy was performed at screening and week 16. Measurement of antibodies to IFX (ATI) was performed at baseline and week 16.
The primary end point of the study was the proportion of patients in CS-free remission, defined as a total Mayo score of 2 points or less, with no individual subscore exceeding 1 point, without the use of CSs at week 16. Secondary end points included the percentage of patients with partial Mayo response at week 8 (defined as a decrease from baseline in partial Mayo score [ie, Mayo score without endoscopy subscore] of 1 point); the percentage of patients with total Mayo response at week 16 (defined as a decrease in the total Mayo score of 3 points and at least a 30% decrease from baseline Mayo score); the percentage of patients with mucosal healing (Mayo endoscopy subscore of 0 or 1) at week 16; and changes in mean Mayo, IBDQ, and SF-36 scores from baseline to weeks 8 and 16. A more lenient definition of Mayo response was used at week 8 than week 16 to provide an earlier rescue treatment for patients with poor response. In post hoc analyses, response at week 8 also was assessed using a more stringent definition of response (decrease from baseline in partial Mayo score of 2).
Monitoring of adverse events (AEs) and use of concomitant medications was performed throughout the study. Safety laboratory measurements consisting of routine hematology and serum chemistry were performed at screening, randomization, and weeks 2, 6, 8, 10, 14, and 16.
Statistical Analysis
The full analysis set consisted of all patients who were randomized, received at least 1 dose of study treatment, and had data available at baseline and at least 1 postbaseline evaluation. The full analysis set was used for analysis of efficacy. Patients who discontinued the study early, were nonresponders at week 8, had missing data for the primary end point at week 16, or took prohibited medications before week 16 were counted as treatment failures (nonremission) for the primary end point at week 16.
The treatment group comparisons for the primary end point of CS-free remission were evaluated using chi-square tests. Treatment group differences in Mayo response at weeks 8 and 16 and mucosal healing at week 16 also were evaluated using chi-square tests. The changes from baseline in Mayo, IBDQ, and SF-36 scores at weeks 8 and 16 were evaluated using the Mann-Whitney U tests.
This study had planned to enroll 600 patients in the initial randomized treatment phase to adequately power the maintenance portion of the study. With 200 patients per group, the study had more than 90% power to detect a 15% difference in remission rate between the AZA and IFX/AZA combination arms with a ¼ .05 (2-sided test), assuming a remission rate of 15% in the AZA arm. Because the study was terminated early, only 239 patients (w80/group) were available for analysis; therefore, the study had approximately 54% power to detect a 15% difference in remission rates between groups at a P value of less than .05.
Hochberg's step-down approach was used to control type 1 error during treatment group comparisons for the primary end point and secondary end point comparisons. First, comparisons for the primary end point were conducted in a prespecified, sequential manner, in the following order: IFX/AZA vs AZA, IFX vs AZA, and IFX/AZA vs IFX. Each sequential test was to be performed only if statistical significance was achieved for the prior test. The stepwise comparisons that were statistically significant for the primary end point determined the allowable comparisons for the secondary efficacy variables. The study was underpowered as a result of early termination, making it likely that some of the initial between-group comparisons would not meet the prespecified cut-off value; nominal P values are provided for all comparisons, and interpretation of those results should be made with caution.
Safety and tolerability were assessed by a statistical and clinical review of all safety parameters, including AEs, laboratory values, and vital signs. The all-patients-as-treated population, which included all randomized patients who received at least 1 dose of study treatment, was used for the analysis of safety data. Because nonresponding patients in the AZA group could receive rescue therapy with IFX starting at week 8, making treatment group comparisons less clear, AEs for the 3 treatment groups are reported only through week 8. Treatment group differences in AEs of special interest (serious infections and hepatobiliary events) and discontinuations owing to AEs were evaluated with the Fisher exact tests. AEs occurring in at least 4 patients in any treatment group were to be summarized using 95% confidence intervals (CIs) for between-group differences.
Results
Patient Disposition
Of the 239 patients who were assigned randomly to treatment, 6 patients had no postbaseline efficacy data, and 2 patients did not receive study treatment; therefore, 231 patients composed the full analysis set population (76 patients received AZA monotherapy, 78 received IFX/AZA combination therapy, and 77 received IFX monotherapy) (Figure 1 ). In the AZA group, 26 patients were nonresponders at week 8 and received rescue therapy with IFX.
Baseline Characteristics
The 3 treatment groups were similar in baseline demographics and disease characteristics, including median fecal calprotectin levels and mean total and partial Mayo scores and endoscopy scores (Table 1) . Although a smaller proportion of patients randomized to the AZA group used corticosteroids at baseline compared with patients randomized to the IFX/AZA group (34.2% vs 47.5%, respectively), this difference was not statistically significant in a post hoc chi-square test (P ¼ .09).
Primary Efficacy End Point: CorticosteroidFree Remission
The primary end point, CS-free remission at week 16 (Figure 2A ). The CS-free remission rates at week 16 were similar for the AZA and IFX monotherapy treatment groups (P ¼ .813). When a sensitivity analysis was conducted, in which the responses of patients who received rescue IFX treatment after failing AZA at week 8 were carried forward to week 16, the results were identical to those obtained in the primary analysis, in which nonresponders were considered treatment failures.
For secondary end points, all P values for comparisons of treatment groups are provided for informational purposes; however, because the second stepwise comparison in the prespecified sequence (IFX vs AZA) did not achieve statistical significance for the primary end point, P values for all comparisons except IFX/AZA vs AZA should be interpreted with caution.
Secondary Efficacy End Points
Mucosal healing. Mucosal healing (Mayo endoscopy subscore of 0 or 1) at week 16 was reached by a greater percentage of patients treated with IFX/AZA combination therapy (62.8%) than AZA monotherapy (36.8%; P ¼ .001) ( Figure 2B) . The difference between the IFX/AZA group and the IFX group (54.6%) was not statistically significant (P ¼ .295). A post hoc analysis was conducted to determine the proportion of patients who achieved a Mayo endoscopy subscore of 0 only at week 16. A greater proportion of patients treated with IFX/AZA combination therapy (29.5%) achieved a Mayo endoscopy subscore of 0 than patients given monotherapy with IFX (11.7%; P ¼ .006) and AZA (13.2%; P ¼ .014). The difference between the IFX group and the AZA group was not statistically significant (P ¼ .783).
Mayo response. At week 8, partial Mayo response
(partial Mayo score improvement from baseline of 1) was attained by a greater percentage of patients receiving IFX/ AZA (85.9%) or IFX monotherapy (88.3%) than AZA monotherapy (65.8%; for IFX/AZA vs AZA, P ¼ .003; Figure 2C ). In a post hoc analysis using the more stringent definition of partial Mayo response (improvement of 2 from baseline), fewer patients met the higher criterion for response, but the pattern of improvement across treatment groups was similar to that obtained using the more lenient prespecified definition ( Figure 2D) . A similar pattern occurred for total Mayo response at week 16 (defined as a decrease in total Mayo score of 3 points and 30% decrease from baseline Mayo score); response was significantly greater in patients who received either IFX/AZA (76.9%) or IFX monotherapy (68.8%) than AZA monotherapy (50.0%; for IFX/AZA vs AZA, P ¼ .001; Figure 2E ).
Change in total Mayo score. At week 16, the mean total Mayo scores had changed from baseline by -3.00 (SD, 3.45), -4.27 (SD, 2.84), and -5.28 (SD, 2.88) in the AZA, IFX, and IFX/AZA treatment groups, respectively ( Figure 2F ). The improvement in total Mayo scores was significantly greater for IFX/AZA combination therapy than AZA monotherapy (P < .001) or IFX monotherapy (P ¼ .028). Table 2 ).
Safety Analysis
Analysis of safety through week 8 included 237 patients who were randomized to treatment and received at least 1 dose of study medication (Table 2 ). Safety data from weeks 8 to 16 were analyzed separately because IFX was added to the treatment regimen of nonresponders to AZA monotherapy at week 8 (Supplementary Table 3 ). Through week 8, at least one adverse event was reported by 38% of patients in the IFX/AZA group (N ¼ 80), 52% of patients in the AZA group (N ¼ 79), and 33% of patients in the IFX group (N ¼ 78). NOTE. Safety analysis included all patients randomized to treatment who received at least 1 dose of study medication. Because AZA monotherapy nonresponders at week 8 received IFX rescue therapy, treatment group comparisons were not as clear after week 8; therefore, the table includes only adverse events reported through week 8. a Hepatobiliary events refer to alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, g-glutamyltransferase, or bilirubin levels per the World Health Organization classification of grade 2 or higher.
b Serious infections included, but were not limited to, tuberculosis, opportunistic infections, salmonellosis, and serious viral infections.
Serious AEs were reported in 4% of patients in the IFX/AZA group (events of anemia, worsening of UC, ineffective drug, dysgeusia, and toxic skin eruption), 8% of patients in the AZA group (events of duodenal ulcer, nausea, acute pancreatitis, vomiting, hyperthermia, pneumonia, headache, pulmonary embolism, and rash), and no patients in the IFX group.
Adverse events leading to discontinuation were numerically higher in the AZA group (8%) than in the IFX group (3%) or the IFX/AZA group (4%), although they were not significantly different (IFX/AZA vs AZA: 95% CI, -11.0 to 3.33, P ¼ .328; IFX vs AZA: 95% CI, -11.8 to 1.78, P ¼ .276; IFX/AZA vs IFX: 95% CI, -4.26 to 6.63, P > .999). Adverse hepatobiliary events were reported by a significantly greater percentage of patients who received AZA (16%; 95% CI, -4.40 to 9.21; P ¼ .720) than IFX/AZA (6%; 95% CI, -20.0 to -0.46; P ¼ .048) or IFX (4%; 95% CI, -21.8 to -3.39; P ¼ .015). For other categories of AEs of interest, there appeared to be no differences between the treatment groups in these types of events, including serious infections (0 in the IFX/AZA group, 1 in the IFX group, and 1 in the AZA group), infusion reactions, tuberculosis, opportunistic infections, malignancies, or lymphomas. Specific events in these categories included 1 event of pneumonia in the IFX group, and 1 event each of pneumonia, drug sensitivity, and infusion-related reaction in the AZA group.
No patients in the IFX monotherapy group reported lifethreatening adverse events. In the AZA monotherapy group, a 52-year-old woman experienced life-threatening acute pancreatitis. In the IFX/AZA combination therapy group, a 51-year-old man experienced life-threatening events of ineffective drug and worsening UC. No deaths occurred in this study or within 30 days of the end of the study.
Antibody status. Only 38% of patients had evaluable antibody samples, and about 60% of these yielded inconclusive results regarding the presence of IFX antibodies (Table 3) . Of patients with evaluable samples at week 16, a greater percentage appeared to be ATI-positive in the IFX monotherapy group (19%; 7 of 37) than the IFX/AZA combination therapy group (3%; 1 of 31). No patients in the AZA group were ATI-positive.
Discussion
The efficacy of IFX in moderate to severe UC was shown clearly in 2 large randomized controlled trials: Active Ulcerative Colitis Trial (ACT) 1 and ACT 2. 4 However, there continues to be a debate about the position of IFX in the therapeutic treatment paradigm and what might be the ideal regimen to optimize efficacy of IFX when treating patients with UC. Currently, AZA (and 6-MP) is considered an established second-line therapeutic agent for UC, and commonly is used in clinical practice. However, the evidence for its efficacy when used in patients with steroid-refractory or steroiddependent disease is not conclusive. [13] [14] [15] In the current study, an IFX-based regimen was superior to AZA alone, similar to the results observed in the Study of Biologic and Immunomodulator Naive Patients in Crohn's Disease (SONIC) in patients with moderate to severe Crohn's disease. 16 The primary efficacy end point in UC SUCCESS was CS-free remission, which is arguably the most relevant outcome to patients. This outcome proved to be achieved most effectively by combination therapy, which yielded a remission rate approximately 2-fold greater than either monotherapy (combination, 40% vs IFX, 22% and AZA, 24%, respectively), an outcome of considerable clinical importance in the treatment of this patient population. In addition to steroid-free remission, the IFX/AZA combination therapy group achieved greater mucosal healing and Mayo response rates than the AZA monotherapy group. Mucosal healing is arguably the most objective measure of disease control, and is an important indicator of disease control in the longer term. 17 Although there was no difference between the IFX and AZA monotherapy groups in the percentage of patients with CS-free remission at week 16, there may have been a difference between these groups in mucosal healing (as defined by a Mayo endoscopy subscore of 0 or 1), achieved by 54.6% of the IFX group and 36.8% of the AZA group. However, the proportion of patients with a Mayo endoscopy subscore of 0 was not significantly different in patients in the IFX group (11.7%) or the AZA group (13.2%) (P ¼ .783). These results should be interpreted with caution because of the relatively small sample size and the lack of a difference between these groups in the primary end point (which guided statistical analysis for the remaining end points). A potential study limitation is that patients in the AZA group may not have had a full chance to experience an improvement in mucosal healing at 8 weeks because of the long time to onset of therapeutic action of AZA.
Treatment with IFX/AZA combination therapy, IFX monotherapy, and AZA monotherapy was well tolerated, and no new safety signals were observed in this study. Although more patients developed hepatotoxicity in the AZA monotherapy group than in the other treatment groups, this resolved with discontinuation of the drug. There were no differences in adverse events of interest, including tuberculosis, opportunistic infections, malignancies, or lymphomas. However, it must be acknowledged that the study was of short duration (adverse events are reported through week 8) and not powered to look at treatment-related differences in safety profiles. Although combination therapy yielded the most robust results for the induction of steroidfree remission in this study, health care providers need to weigh the benefits of combination therapy against potential safety risks that have been observed with combination therapy (ie, hepatosplenic T-cell lymphoma). A recent analysis of data from the SONIC study showed that the overall value of combination therapy significantly outweighs the risks in patients with Crohn's disease. 18 This study had several limitations. UC SUCCESS originally was designed to continue beyond the 16-week study reported here to evaluate 2 possible strategies for maintaining steroid-free remission. Unfortunately, the study was terminated prematurely because data from a separate study of IFX for treatment of psoriasis indicated that an intermittent maintenance treatment regimen was associated with a greater number of infusion reactions. Therefore, the ideal IFX treatment protocol for UC maintenance therapy will remain an important topic for future studies. The early termination of the study also resulted in reduced statistical power to detect differences between groups. For this reason and because the step-down sequence of statistical testing indicated that only the combination treatment vs AZA comparisons could be declared statistically significant, the other group comparisons reported here should be interpreted with caution. However, the consistent superiority of combination AZA/IFX treatment over AZA alone across several efficacy end points is a clear outcome of the study.
Another limitation of the study was the small amount of evaluable data for IFX antibody analysis. Future studies with larger patient populations may be able to determine the relationship between remission rates and IFX antibody production.
In conclusion, the combination of IFX and AZA was superior to AZA monotherapy in inducing steroid-free remission in anti-TNF-naive patients with moderate to severe UC who previously had an inadequate response to CSs with or without mesalamine. The results of this study suggest that an IFX-based strategy may be helpful in patients with moderate to severe UC who previously had an inadequate response to CSs with or without mesalamine.
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